^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

LMO2 overexpression

i
Other names: LMO2, LIM Domain Only 2, Rhombotin-Like 1, T-Cell Translocation Protein 2, T-Cell Translocation Gene 2, Cysteine-Rich Protein TTG-2, LIM Domain Only Protein 2, RBTNL1, RBTN2, RHOM2, TTG2, Rhombotin-2
Entrez ID:
9ms
Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia. (PubMed, Hemasphere)
We also showed that MYB is a dependency factor in T-ALL since RNA interference of Myb blocked cell cycle progression and induced apoptosis in both human and murine T-ALL cell lines. Finally, we provide preclinical evidence that targeting the transcriptional activity of MYB can be a useful therapeutic strategy for the treatment of T-ALL.
Journal
|
PTEN (Phosphatase and tensin homolog) • MYB (MYB Proto-Oncogene, Transcription Factor) • LMO2 (LIM Domain Only 2)
|
PTEN deletion • LMO2 overexpression
9ms
LMO2 RNA ISH Expression Correlates with LMO2 Protein and Gene Expression and Captures their Survival Impact in Diffuse Large B-Cell Lymphoma, NOS (USCAP 2024)
LMO2 ISH by RNAscope method is reliable and can be applied in routine FFPE samples. Our series had good correlation with LMO2 gene expression and LMO2 IHC. Moreover, the prognostic impact on survival captured by LMO2 RNA ISH was similar to published for gene expression and IHC methods.
LMO2 (LIM Domain Only 2)
|
LMO2 overexpression
|
HTG Transcriptome Panel
1year
A Dual Role of SOX11 Expression in the Formation of T-Cell Acute Lymphoblastic Leukemia in Mouse Models (ASH 2023)
By generating multiple models of SOX11 expression in the T-cell lineage, we showed that SOX11 impacts T-cell differentiation, both in mice and humans, and that it can promote or hinder T-ALL formation depending on the oncogenic driver.
Preclinical
|
PTEN (Phosphatase and tensin homolog) • CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • LMO2 (LIM Domain Only 2) • SOX11 (SRY-Box Transcription Factor 11)
|
LMO2 overexpression • SOX11 expression • CD4 positive
over1year
LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1. (PubMed, Cell Death Dis)
In LDB1-deficient AML cell lines, the overexpression of LMO2 partially compensates for the proliferation inhibition. In summary, our findings revealed that LDB1 played an important role in AML as an oncogene, and emphasize the potential importance of the LMO2/LDB1 complex in clinical treatment of patients with AML.
Journal
|
LMO2 (LIM Domain Only 2)
|
LMO2 overexpression
over1year
PARP INHIBITORS ARE EFFECTIVE IN NATURAL KILLER/T CELL LYMPHOMA VIA THE EXPRESSION OF LMO2 (EHA 2023)
Finally, the combination of fluzoparib and cisplatin exhibited significant synergistic effects both in vitro and in vivo . In summary, we found that PARPis exerted an anti-lymphoma effect in NKTCL, and the underlying mechanisms may be "synthetic lethality-like" via LMO2 expression. Moreover, LMO2 may be a novel indicator for drug sensitivity and prognosis in NKTCL. These findings offer a foundation for the clinical application of PARPis and provide certain implications for the clinical management of NKTCL.
PARP Biomarker
|
LMO2 (LIM Domain Only 2)
|
LMO2 overexpression
|
cisplatin • AiRuiYi (fluzoparib)
over1year
Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition. (PubMed, J Exp Med)
Genomic analyses revealed the presence of Notch1 mutations in pre-LSCs before subsequent loss of tumor suppressors promotes the transition to overt leukemogenesis. These studies demonstrate a critical role for impaired cell competition in the development of pre-LSCs in a transgenic mouse model of T cell acute lymphoblastic leukemia (T-ALL), implying that this process plays a role in the ontogeny of human T-ALL.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • LMO2 (LIM Domain Only 2)
|
NOTCH1 mutation • BCL2 expression • LMO2 overexpression
over3years
[VIRTUAL] CROSSING OUR T'S: AN UNUSUAL PRESENTATION OF INFANTILE T-CELL LEUKEMIA (ASPHO 2021)
The paucity of data regarding infantile T-ALL’s clinical presentation, management, genomics, and outcomes results in difficult treatment decisions including potential use of agents such as Nelarabine, at a young age... We report a unique case of infantile T-ALL, treated initially per COG protocol AALL0631. With CSF3Rmutations association to GCSF, being an unusual finding. Additionally, LMO2 overexpression is a common driver of T-Cell malignancies, however, has not been reported in infantile T-ALL.
CSF3R (Colony Stimulating Factor 3 Receptor) • LMO2 (LIM Domain Only 2)
|
MLL rearrangement • LMO2 overexpression
|
FoundationOne® CDx
|
nelarabine